Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first precision medicine combo for patients with BRCA2-mutated metasta | Akeega, a ...

In 2013, a prostate-specific antigen (PSA) blood test revealed that Richard LaFrate's levels had jumped. Previously in a normal range, LaFrate's PSA was now above 6 ng/mL, indicating an elevated ...

Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data. Among patients with metastatic hormone-sensitive prostate cancer, the ...

For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...